India's Shilpa Medicare can
make 100-200 million doses of
Indian drug maker Shilpa Medicare Ltd has the production
capacity to make 100-200 million doses of a recombinant vaccine
for COVID-19, a company executive told Reuters on Wednesday.
The company's shares jumped as much as 9.2% on India's
National Stock Exchange following the news. Read More